BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Durfey SL, Pipavath S, Li A, Vo AT, Ratjen A, Carter S, Morgan SJ, Radey MC, Grogan B, Salipante SJ, Welsh MJ, Stoltz DA, Goss CH, McKone EF, Singh PK. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. mBio 2021;12:e0314821. [PMID: 34903059 DOI: 10.1128/mbio.03148-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Hogan AM, Maydaniuk DT, Natarajan A, Léon B, Batun Z, Motnenko A, Bosch A, Cardona ST. Profiling cell envelope-antibiotic interactions reveals vulnerabilities to β-lactams in a multidrug-resistant bacterium.. [DOI: 10.1101/2022.11.01.510852] [Reference Citation Analysis]
2 Pallenberg ST, Pust MM, Rosenboom I, Hansen G, Wiehlmann L, Dittrich AM, Tümmler B. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome. Microbiol Spectr 2022;:e0145422. [PMID: 36154176 DOI: 10.1128/spectrum.01454-22] [Reference Citation Analysis]
3 Cogen JD, Nichols DP, Goss CH, Somayaji R. Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections. J Pediatric Infect Dis Soc 2022;11:S32-9. [PMID: 36069901 DOI: 10.1093/jpids/piac061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cramer N, Nawrot ML, Wege L, Dorda M, Sommer C, Danov O, Wronski S, Braun A, Jonigk D, Fischer S, Munder A, Tümmler B. Competitive fitness of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slices. Front Cell Infect Microbiol 2022;12:992214. [DOI: 10.3389/fcimb.2022.992214] [Reference Citation Analysis]
5 Greenwald MA, Wolfgang MC. The changing landscape of the cystic fibrosis lung environment: From the perspective of Pseudomonas aeruginosa. Current Opinion in Pharmacology 2022;65:102262. [DOI: 10.1016/j.coph.2022.102262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saluzzo F, Riberi L, Messore B, Loré NI, Esposito I, Bignamini E, De Rose V. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells 2022;11:1243. [DOI: 10.3390/cells11071243] [Reference Citation Analysis]
7 Harvey C, Weldon S, Elborn S, Downey DG, Taggart C. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis. Int J Mol Sci 2022;23:3513. [PMID: 35408875 DOI: 10.3390/ijms23073513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cigana C, Giannella R, Colavolpe A, Alcalá-franco B, Mancini G, Francesca C, Bigogno C, Bastrup U, Bertoni G, Bragonzi A. Linking CFTR modulators to opportunistic bacterial infections in cystic fibrosis.. [DOI: 10.1101/2022.02.15.478594] [Reference Citation Analysis]